The trademark application BAKALVIO was filed by AstraZeneca AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on June 15, 2016, and it was registered by office on September 22, 2016 without any oppositions.
The application was filed in English (French was selected as the second language).